Financials
Financial year 2024
ACLOT PHARMA from Nivelles, company number BE0456857330, closed financial year 2024 with a result of € 46,977 after tax. For that financial year ACLOT PHARMA recorded a gross margin of € 361,806 and equity of € 126,788. Compared with financial year 2023, the result moved from € -6,721 to € 46,977. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 4, 2025.
€ 126,788
▲ 6% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 46,977
▲ still € 6,721 loss in 2023
Profit after tax over the fiscal year.
€ 171,054
▲ 74% vs 2023
Cash and bank balances on the last day of the fiscal year.
€ 40,000 paid out
85 % of the profit went to the shareholders, mostly to PHARMANEXT (100 % of the shares). That is where the money ends up.
People and assets in 2024
2.4
Average over the fiscal year, from the social balance sheet.
€ 192,914
▲ 3% vs 2023
€ 80,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2024
€ 436,667
▼ 8% vs 2023
€ 40,000 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.
€ 35,448
▼ 43% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 33,297
▲ 13% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 258,744 | € 313,802 | € 303,698 | € 361,806 | ▲ 19% |
| Profit after taxes | € -3,596 | € 25,438 | € -6,721 | € 46,977 | ▲ € 53,698 |
| Equity | € 101,093 | € 126,531 | € 119,811 | € 126,788 | ▲ 6% |
| Total debts | € 1,107,082 | € 1,318,898 | € 1,279,724 | € 1,256,505 | ▼ 2% |
| Cash | € 181,688 | € 86,511 | € 98,581 | € 171,054 | ▲ 74% |
| Land & buildings | € 417,546 | € 401,435 | € 385,324 | € 369,213 | ▼ 4% |
| Retained profit | € 82,493 | € 107,931 | € 101,211 | € 108,188 | ▲ 7% |
| Dividend | € 0 | € 0 | € 0 | € 40,000 | |
| Bank debt | € 556,667 | € 516,667 | € 476,667 | € 436,667 | ▼ 8% |
| Balance sheet total | € 1,208,175 | € 1,445,429 | € 1,399,535 | € 1,383,293 | ▼ 1% |
| Employees (FTE) | - | - | 2.4 | 2.4 |
Key figures of ACLOT PHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to ACLOT PHARMA?
What happened at ACLOT PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 46,977. Source: NBB ↗
- New establishment in Nivelles. KBO
- Start of the company according to the CBE. KBO
In short
From € 3,596 loss in 2021 to € 46,977 profit in 2024.
Paid € 1,580 in corporate taxes since 2021.
Best year ever: 2024, with € 46,977 profit.
On average € 150,800 of value added per employee in 2024.
A new publication or filing at ACLOT PHARMA? We notify you, reason included.
Follow ACLOT PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of PHARMANEXT comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
ACLOT PHARMABehind ACLOT PHARMA are GFCS SCS, Nadine Demeulemeester, PHILIPPE DEHAYE and EGUIMAX SCS. The shares are held by PHARMANEXT (100%).
Directors
According to the 2024 annual accounts
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue du Paradis 101
1400 Nivelles
Rue Sainte-Anne 8
1400 Nivelles
Active since 29 February 1996
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0456.857.330
- VAT number
- BE 0456.857.330
- Registered office
- Rue du Paradis 101, 1400 Nivelles
- Names & denominations
- ACLOT PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 20 December 1995
- Peppol
- Active · Active since 23 Sept 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers